

Congress of the United States
House of Representatives

COMMITTEE ON OVERSIGHT AND ACCOUNTABILITY

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
MINORITY (202) 225-5051
<https://oversight.house.gov>

July 5, 2023

William Weissinger
Division Director, OHAF-East Division 6
Office of Regulatory Affairs
U.S. Food and Drug Administration
550 W. Jackson Blvd, Room 1500
Chicago, IL 60661

Dear Mr. Weissinger:

The Committee on Oversight and Accountability Subcommittee on Health Care and Financial Services is continuing to investigate the U.S. Food and Drug Administration's (FDA) response to the 2022 infant formula shortage. Based on our investigation, the Subcommittee believes you have valuable information that will inform its understanding of the FDA's response to this crisis. We therefore request that you make yourself available for a transcribed interview.

To schedule the transcribed interview or ask any related follow-up questions, please contact the Committee on Oversight and Accountability Majority Staff at (202) 225-5074 no later than July 12, 2023.

The Committee on Oversight and Accountability is the principal oversight committee of the U.S. House of Representatives and has broad authority to investigate "any matter" at "any time" under House Rule X.

Sincerely,



Lisa McClain
Chairwoman
Subcommittee on Health Care and Financial Services

cc: The Honorable Katie Porter, Ranking Member
Subcommittee on Health Care and Financial Services